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ABSTRACT 
In females, peak bone mineral velocity is attained at approximately 12 years of age, with 
bone mass accrual plateauing at around age 18 years. Optimizing bone accrual during growth is 
believed to prevent osteoporosis and related fracture risk later in life. A number of lifestyle 
factors such as physical activity and diet are known to influence bone accrual. In addition, 
estrogen plays a key role and is a main component affected by oral contraceptives (OC). OC are 
becoming commonly prescribed for females from 12 years of age. Currently, research on the 
impact of OC use at this age on bone development is equivocal. Therefore, the purpose of this 
study was to use a longitudinal study to compare bone mass between OC users and non-users 
during adolescence and young adulthood.  
One hundred and twenty-one female participants were drawn from the University of 
Saskatchewan’s Bone Mineral Accrual Study (BMAS). Participants were grouped based on the 
initiation and duration of OC use. Bone mineral content (BMC) and areal bone mineral density 
(aBMD) were assessed by Dual Energy X-Ray absorpitometry. Questionnaires were used to 
ascertain OC use. BMC and aBMD were assessed between groups at each biological age (BA) 
using ANCOVA (covariates: height, lean mass, physical activity, vitamin D and calcium). BA is 
the years from peak height velocity (PHV).  
Individuals who had initiated OC use after 18 years of age were shown to have, at 30 
years of age, significantly less total body (TB) BMC than those individuals that had never used 
OC. In contrast, persons who initiated OC use between the years of 12 and 18 did not have 
significantly different TB BMC, between the ages of 20 to 30 when compared to non-users and 
users who initiated after 18 years of age. OC usage between 12 to 18 years significantly 
improved lumbar (LS) spine BMC 7 years post PHV.  It was found aBMD was not significantly 
influenced by duration of OC use.  
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When OC use began during adolescence there did not appear to be a detrimental effect on 
TB bone accrual at 30 years. However, it was found that LS accrual was enhanced at 
approximately 19 years of age, a difference that was no longer evident by 30 years. 
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1.0 INTRODUCTION 
1.1 Osteoporosis 
Osteoporosis is a disease typically affecting the elderly although its onset can occur at 
any age. The prevalence of osteoporosis is growing in Canada, with two million Canadians 
currently diagnosed (Osteoporosis Canada, 2010). It is a disease that affects 1 in 4 women, in 
comparison to 1 in 8 men.  
Osteoporosis is characterized by low bone mineral density, deterioration of 
microarchitectural bone tissue and increased fracture risk (Kanis, Melton, Christiansen, Johnston, 
& Khaltaev, 2009). Osteoporosis is defined as an areal bone mineral density (aBMD) T score 
less than 2.5 standard deviations (SD) from the norm, based on BMD as a healthy young adult 
(Kanis et al., 1994). The majority of fractures occur at the hip and spine, which increases the risk 
of mortality in the year following the fracture (Busen, 2004). It would appear prudent therefore 
to better understand the process of bone accrual and the factors affecting bone accrual in order to 
reduce the risk of osteoporosis and death. 
 
1.2 Bone Accrual 
Bone accrues during childhood and adolescence through the action of continuous 
resorption and formation of bone cells. While 25% of the adult bone mass is accrued during the 2 
years spanning the adolescent growth spurt (approximately 12 years of age in girls and 14 years 
in boys) (Baxter-Jones, Faulkner, Forwood, Mirwald, & Bailey, 2011; Bailey, McKay, Mirwald, 
Crocker & Faulkner, 1999), a further 50% increase in total bone mass accrual occurs between the 
ages of 12-18 years in females (Cromer, Bonny, Stager, Lazebnik, & Secic, 2008). This is 
important to note since bone mass peaks at approximately 18 years and starts to decline at the 
end of the third decade of life (Frost, 1997; Busen, 2004; Baxter-Jones et al., 2011), with the 
largest drop off of bone mass occurring in concurrence with menopause. Therefore, if enough 
bone is not laid down during the growth period, with the age-related decline in bone mass, 
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women are at higher risk for osteoporosis. As such, this would suggest that the antecedents of 
bone disease are in childhood. Previous cross-sectional (Ferretti, Capozza, Cointry, Garcia, 
Plotkin et al., 1998), short-term (Theintz, Buchs, Rizzoli, Slosman, Clavien, Sizonenko et al., 
1992) and longer-term longitudinal studies (Maynard, Guo, Chumlea, Roche & Wisemandle, et 
al., 1998), suggest that bone mass, represented by total body (TB) bone mineral content (BMC) 
accrual values, are similar (for girls) before puberty (9 to 11 years of age). At puberty there is a 
marked acceleration in both linear height and bone mineral accrual with peak height velocity 
(PHV) being reached on average 8 months before peak bone mineral content velocity (Bailey et 
al., 1999). However, the timing (chronological age at peak) and magnitude of these maturational 
events vary systematically and markedly between individuals (Bachrach, Hastie, Wang, 
Narasimhan, & Marcus, 1999). In the longitudinal Saskatchewan Pediatric Bone Mineral Accrual 
Study it was found that the timing of peak BMC accrual occurred on average 1.5 years earlier in 
girls than in boys, and coincided in girls with the timing of menarche (McKay, Bailey, Mirwald, 
Davison & Faulkner, 1998). Longitudinal studies of human somatic growth have clearly 
demonstrated that although the pattern of linear growth is consistent within the human species, 
the timing and magnitude of growth is a highly individualized process. It has also been 
demonstrated that this is true for the pattern, magnitude and timing of bone mineral accrual in the 
human skeleton (Bailey et al., 1999). To adequately distinguish individual differences during 
childhood in the pattern of bone mineral accrual individuals must be studied at comparable 
biological rather than chronological ages (Molgaard, Thomsen, & Michaelsen, 1999). One way 
to do this is to identify individual growth trajectories; something that can only be achieved using 
longitudinally gathered data. The uniqueness of this approach is that it accounts for the wide 
variation shown amongst children’s growth parameters at any given age, and in the velocity of 
these parameters from one age to the next (Tanner, 1962). Thus, researchers are able to assess 
bone growth in the time before and after PHV. This time of accelerated bone growth is a period 
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when influential environmental factors such as physical activity, diet and oral contraception 
usage may have a significant impact on bone accrual.  
 
1.3 Environmental Factors 
Genetics account for 60 to 80 % of bone mass accrual, with environmental factors and 
lifestyle accounting for a further 20-40% (Ruffing, Nieves, Zion, Tendy, Garrett, et al., 2007). 
Although there are many factors that influence bone, probably the most influential affecting bone 
growth and bone maintenance are physical activity (PA), diet and the hormonal milieu. 
Physical Activity has been shown to be beneficial to the accrual of BMC during puberty 
(Bailey et al., 1999).  High impact loading activities such as tennis, running and gymnastics are 
among the activities that are beneficial to effectively accruing bone (Bailey et al., 1999; McKay, 
Petit, Schutz, Jerilynn, Barr et al., 2000). As the skeleton matures, PA intensifies the amount of 
bone accrued (Bailey et al., 1999); therefore, it is important to consider PA levels and their 
implications on bone when assessing changes in BMC during growth. 
Calcium (Ca) supplementation has also been shown to facilitate adequate bone mineral 
deposition during growth, especially around the time of PHV (Bailey et al., 1999). Intake of 
calcium, (1000 mg/d for girls), is necessary to increase bone accrual during the adolescent 
growth period (Vantanparast, Bailey, Baxter-Jones & Whiting, 2009). Vitamin D is also an 
essential nutrient for bone development. This nutrient can be obtained through sun exposure and 
dietary intake. Vitamin D is necessary for proper tissue formation and the achievement of full 
stature potential (Malina, Bouchard & Bar Or, 2004). Vitamin D deficiency is associated with 
osteoporotic fractures and it is suggested that 10 µg/d is necessary to improve or maintain bone 
health as well as increase bone mass of the growing skeleton (Institute of Medicine, 2010; 
Vantanparast, Calvo, Green, & Whiting, 2010). Since Vitamin D and Ca each have a high impact 
on bone accrual it is important to control for diet when assessing bone parameters.  
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The hormonal milieu has also been shown to be an important factor influencing bone 
accrual. Estrogen levels increase during puberty (Busen, 2004) due to the onset of the menstrual 
cycle, while the cessation of menses at menopause, results in a decrease in the circulating level 
of estrogen. Estrogen is secreted throughout the menstrual cycle to aid in the growth of a 
dominant follicle, which in turn grows and secretes more estrogen.  High levels of estrogen lead 
to optimal peak levels of bone growth and bone maintenance since estrogen suppresses cell 
apoptosis of osteoblasts cells, which are essential in bone modeling and remodeling (Corwin, 
2008).  Estrogen also aids in the fusing of the epiphyseal plates at skeletal maturation in order to 
complete linear growth (Cutler, 1997). With a deficiency of estrogen, bone resorption increases, 
without an equivocal rise in bone formation (ESHRE Capri Workshop Group, 2010) leading to a 
potential decline in bone mass. It is known that hormones are affected by a number of factors 
with pharmacological agents often used as manipulative factors. Hormonal contraceptives (HC) 
are pharmacological agents that affect the level of circulating estrogen in the body. Progesterone 
in HC suppresses the levels of estrogen; therefore preventing the growth of estrogen-induced 
follicles, which in turn reduces peak amounts of estrogen during the menstrual cycle, ultimately 
resulting in decreasing circulating estrogen (Reed, Scholes, LaCroix, Ichikawa, Barlow, Ott et 
al., 2003). Although the question of whether lower doses of estrogen in HC suppress bone 
formation has been studied (Cromer et al., 2008), the effects of HC on bone mineral accrual 
remain equivocal, as research to date has demonstrated both a positive and negative impact. Oral 
contraceptive (OC) use is now more common during puberty and is continuing for longer periods 
of time. The question remains whether use of OC has a detrimental effect on bone health and 
more specifically, whether use during adolescence and young adulthood affects accrual of bone 
mineral content in the immediate and long-term future.  
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1.4 Purpose 
The purpose of this study was to assess the long-term effects of OC use during 
adolescence and young adulthood on subsequent bone mineral accrual for the Total Body (TB), 
and at the Lumbar Spine (LS) and Femoral Neck (FN). 
 
1.5 Hypothesis 
1. It was hypothesized that non-users of OC will have greater TB, LS and FN BMC in 
comparison to OC users.  
2. It was hypothesized that those individuals who use OC for a longer duration will have 
significantly lower bone mineral content than those that have used for a lesser time and non-
users.  
3. It was also hypothesized that those individuals that initiated OC during adolescence 
would have a greater decrease in bone mineral accrual than those individuals that initiated use in 
young adulthood.  
 
2.0 LITERATURE REVIEW 
 Given the focus of this study, this review of literature will be limited to a review of 
musculoskeletal health during growth. While the interplay between endocrinology and bone 
health will be discussed it is not the focus of this review, and will be restricted to only those 
research studies directly applicable to the proposed research study.  
 
2.1 Osteoporosis 
Osteoporosis is a disease characterized by low bone mineral density (BMD), 
microarchitectural tissue deterioration and increased fracture risk (Osteoporosis Canada, 2011; 
Consensus Development Conference, 2000). It currently affects over 2 million Canadians 
(Osteoporosis Canada, 2011). Osteoporosis occurs without symptoms and is difficult for people 
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to know they have it (Osteoporosis Canada, 2011; Ioannidis, Papaioannou, Hopman, Akhtar-
Danesh, & Anastassiades, 2009). However, tools are available to assess risk of osteoporotic 
levels and preventative strategies, as well as medications (Osteoporosis Canada, 2011; Ioannidis 
et al., 2009).  
Osteoporosis is defined as aBMD T scores below 2.5 SD from the norm, based on BMD 
as healthy young adult (Kanis, Melton, Christiansen, Johnston & Khaltaev, 1994). Bone is 
comprised of both cortical and trabecular compartments. While cortical bone is the dense 
calcified bone that is found on the exterior compartment of bone, trabecular bone is a porous 
structure typically located in the vertebrae and at the proximal and distal ends of long bones 
(Khan, McKay, Kannus, Bailey, Wark et al., 2001). Osteoporosis is most evident in the 
trabecular bone and primarily affects areas of the body such as the lumbar spine, femoral neck, 
and radius (Dennison, Mohamed & Cooper, 2006; Rickelund, Carlstrom, Ekblom, Brismar, 
Schoutlz, et al., 2004). These high-risk areas are prone to fracture especially when unexpected 
falls occur. Once a fragility fracture of the hip or spine occurs, death often occurs within 5 years 
(Ioannidis et al., 2009). In fact the rise in risk factor increases up to 3 times for fractures as the 
aBMD moves 1 negative SD away from the norm (Kanis et al., 1994). 
Women are typically more affected, with its occurrence as high as one in four after the 
age of 50; in comparison males show a ratio of one in eight (Osteoporosis Canada, 2011).  It is 
thought women are more commonly affected due to the lower estrogen amounts at the onset of 
menopause in comparison to that which is evident through the years of menstruation (Wei, 
Winzenberg, Laslett, Venn & Jones, 2010). Also, prolonged irregular menstruation and other 
estrogen deficient ailments during the menstrual years can lead to osteoporosis (Wei et al., 2010; 
Rickelund et al., 2004).  This is important as estrogen protects bone-building cells from cell 
death (ESHRE Capri Workshop Group, 2010), which is essential to maintaining bone 
homeostasis. Osteoporosis related fractures have an economic burden to Canadian health care 
costs of over 1.9 billion dollars (Osteoporosis Canada, 2011). The lengthy recovery time from 
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osteoporotic fractures is detrimental to the individual’s health and drives up the cost of health 
care annually. Of each fracture occurring in persons over the age of 50, over 80% are due to 
osteoporosis (Osteoporosis Canada, 2011; Osteoporosis Canada-White Paper, 2011) In 1993, 
25,000 people had a osteoporotic related hip fracture (Osteoporosis, 2011), that number has now 
grown to 30,000 per year (Osteoporosis Canada-White Paper, 2011). 
Osteoporosis is a disease that affects adults, however, it is believed that its antecedents 
are in childhood; therefore, the childhood environment is critical for long-term bone health. PA 
and diet play an important role in accruing and maintaining bone health (Kannus, 1999) and in 
order to prevent osteoporosis it is essential that enough bone be laid down during the adolescent 
years, a critical growth period. The timing of bone accrual is important as growth stops at the end 
of the second decade of life and maintenance occurs between 20 and 50 years of age (Baxter-
Jones et al., 2011). It is therefore important to look at how bone accrues and the factors that 
affect bone accrual in order to prevent this disease.   
 
2.2 Bone Development 
2.2.1 Bone Physiology 
Bone is the platform of the skeleton that provides a basic structure (Drake, Vogl & 
Mitchell, 2005). It also produces red blood cells and stores minerals for the human body (Malina 
et al., 2004).  Bone structure is a lifelong process of accrual and maintenance. Bones are in a 
constant dynamic process of modeling and remodeling (Malina et al., 2004). Bone modeling and 
remodeling occur during the original process of forming the adult skeleton, and remodeling, the 
constant recycling and rebuilding of bone, maintains the mature skeleton once bone modeling 
has ceased. During childhood and adolescent years bones are being modeled to acquire the 
mature adult skeleton. Bone is compromised of a bone matrix, which is a manifest action of 
collagen fibers and calcium and phosphorus minerals (Khan et al., 2001). Bone cells: osteocytes, 
osteoclasts and osteoblasts are responsible for the growth and maintenance of bone. Primarily the 
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osteoclasts begin resorption within the matrix in order to keep shape to the bone that is growing 
in width. Once osteoclasts have finished resorption they manifest into osteoblasts. The osteoblast 
deposit bone on the outer layers of the bone through the production of calcium. Osteoblasts are 
then trapped in the matrix and converted into osteoclasts, which mineralize the collagen fibers 
with calcium and phosphorus minerals.  
Both a growth in length and width occur during the remodeling stage. Growth in length 
takes place at the growth plate of each bone (Rauch, 2005), which separates the epiphysis and 
metaphysis (Figure 2.1).  
 
Figure 2.1 – Long Bone Diagram 
 
(Dayton Children’s, 2011) 
 
Figure Description: the lines separating the epiphysis and metaphysis depict the growth plate.  
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Lengthening is due to modeling at the growth plates that are located at the ends of the 
long bones. Once full maturity has been reached, the growth plates fuse between the epiphysis 
and diaphysis and desist any further growth in length.  
 Bone width is achieved by the process of deposition on the outer surface of the periosteal 
layer (Khan et al., 2001); as the bone is increased on the outer surface, osteoclasts absorb the 
matrix from within the bone on the endocortical area creating a constant cycle of increase in 
width (Khan et al., 2001). Shape is maintained through compression and tension on the bone 
surface in order to inhibit and enhance bone growth (Rauch, 2005). Mild tension is believed to 
increase bone growth, and when small deformities occur, negative feedback from daily 
mechanical forces repair bone deformity (Rauch, 2005).  
 
2.2.2 Bone Accrual in Adolescents 
The process of bone modeling occurs throughout childhood and adolescence with a 
higher rate of bone deposition than bone resorption until full skeletal maturity has been reached. 
During the adult years bone is in the state of maintenance where there is a delicate balance of 
resorption and formation. Females continue to lay down new bone at a high rate until they are 18 
years of age; this growth tends to be complete at approximately 20 years of age (Baxter-Jones et 
al., 2011).  From this point bone remodeling takes over which is the same process of new bone 
being formed by osteoblast cells and old bone being resorbed by osteoclast cells as with 
modeling; however, a balance of the two processes exists.  Even though bone loss is slight during 
these years (Frost, 1997) it is not until older age, typically after menopause in women, where 
resorption is at its highest in comparison to deposition, tilting the scales towards bone loss and 
osteoporotic levels  (Cromer et al., 2008; Seeman, 2003). 
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2.3 Growth and Development 
2.3.1 Timing of Maturation 
Humans have similar skeletal growth patterns; however the timing of when the pattern 
occurs varies in accordance to each individual’s timing and tempo of maturation (Baxter-Jones, 
Mirwald, McKay, & Bailey, 2003). In order to document and compare growth, statural growth 
charts are derived from a series of annual or bi-annual measurements over a long term to indicate 
the pattern of growth for each individual, typically from a pre-mature to post-mature age. These 
patterns are made of several small curves of velocity of change (tempo), spanning a distance of 
growth (timing) (Tanner, 1978).  Several small velocity curves exist which are unique to each 
person, yet there is a significant increase in velocity, deemed the adolescent growth spurt, 
occurring between the ages of 10 and 12 for females and 13 and 15 for males (Khan, et al., 
2001). This velocity of growth indicates the speed of growth in which the child increases in 
stature at a specific time point and magnitude unique to them.  
From the time of birth, growth rate steadily declines until the adolescent growth spurt. 
Thus the growth spurt can be utilized as a point of maturation; maturity is reached once adult 
stature is fully attained. In some individuals there is also a mini growth spurt occurring between 
the ages of 6 and 8 years (Tanner, 1978).  It is important to emphasize that these velocities of 
growth are different from individual to individual and that each child will have his or her growth 
spurt at a different time point relative to chronological age. Thus, chronological age during the 
adolescent growth spurt is a poor reflection of an individual’s maturity. An alternative; therefore, 
is to align individuals using a measure of biological or maturational age. 
In order to compare individuals, a curve must be fitted to each child’s growth in stature 
(Tanner, 1978).  This combines the several minute velocities of growth in individuals and leaves 
the distinct projection of change in speed of growth, the velocity curve. Once this curve is fitted, 
growth curve patterns appear as an “S” shape (Tanner, 1978). The rapid acceleration of growth is 
evident and can further be assessed on velocity charts where centimeters per year are plotted.  
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Once velocity charts are plotted, comparison between individuals are not reliable unless lined up 
by time of PHV. PHV is the peak of the velocity curve and is considered an index of biological 
age (BA). Aligning by BA discounts the difference in timing of PHV and compares individuals 
based on their maturational status. Therefore it is pertinent to align by biological age rather than 
chronological age to make comparisons between individuals during adolescence (Malina, 1978). 
 
2.3.2 Maturational Measures 
Somatic growth is a measurement of maturity that utilizes the assessment of the body’s 
growth. This is the most important and widely used indicator of maturation in longitudinal 
growth studies. Velocity of growth is determined by a series of standing height measurements 
(cm/yr) (Bailey et al., 1999). Plotting velocity charts, the magnitude of growth will indicate an 
age where peak height is reached. At the age of this peak height, maturational age named 
biological age (BA) is determined. BA is set to zero, and accumulated there forth. One year after 
PHV, peak BMC is attained (Bailey et al., 1999). PHV allows for a constant in measurement and 
alignment amongst individuals in order to compare growth patterns, while controlling for 
maturational differences. Controlling for height is important, as an individual who is taller will 
have more BMC, yet may not yield a higher bone density. Also, when comparing between sexes 
it is important to note that in females skeletal maturation is achieved between the ages of 10 and 
12 (Malina, 1978), while in males it occurs approximately two years later. Alignment by PHV 
allows researchers to assess and compare growth between individuals prior to and after PHV 
(Malina, 1978). Regardless of maturational measurement used, the marker must be used 
throughout the data collection series of the longitudinal study for reliability. 
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2.4 Hormonal Milieu 
2.4.1 Hormones 
Hormones such as estrogen play a key role in bone accrual (Cromer et al., 2008). 
Estrogen’s role is to suppress cell apoptosis of osteoblasts, which are essential in bone 
remodeling (ESHRE Capri Workshop, 2010); therefore, allowing the osteoblasts to continue the 
production of bone. In individuals with a deficiency in circulating estrogen, such as 
oligiomenorrhea or menopause, bone resorption activity increases, without a subsequent increase 
in bone formation, leading to bone loss (ESHRE Capri Workshop Group, 2010).  
During adolescence the balance between bone resorption and formation is imperative for 
bone health, particularly during the onset of the menstrual cycle when levels of estrogens are 
increased. Due to lifestyle factors, such as OC use, the menstrual cycle and associated hormone 
balance may be altered and the delicate balance of bone maintenance shifted.  
 
2.4.2 Menstrual Cycle 
The onset of menstruation (menarche) occurs approximately 1 year after PHV (McKay et 
al., 1998). Hormones increase at the age of puberty with the onset of the menstrual cycle. The 
menstrual cycle is controlled by the hypothalamus, which secretes gonadotropin-releasing 
hormone into the hypothalmo-pituitary portal (Molina, 2009).  Each cycle’s function is to 
produce an egg (Molina, 2009).  The menstrual cycle is divided into 2 phases: follicular and 
luteal. Each phase lasts 14 days and involves 5 main reproductive hormones: follicular 
stimulating hormone (FSH), luteinizing hormone (LH), estrogen, progesterone, and inhibin. 
Estrogen levels rise at the onset of the 28-day cycle and signal the secretion of FSH and 
luteinizing hormone LH from the pituitary gland (Molina, 2009). FSH and LH act upon the 
follicle located in the ovaries to foster the growth and production of an egg (See Figure 2.4 a and 
b).  
 
 13 
Figure 2.4 Oral Contraceptive Effects on the Menstrual Cycle 
a)  
 
b) 
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c)  
 
(a) Baerwald, Adams & Pierson, 2011; b) Baerwald & Pierson 2003,  
 c) Adapted from Baerwald & Pierson, 2003) 
 
Figure Description:  a) Regular Menstrual Cycle. Days 1-7 (Menses), Days 1-14 (Follicular Phase). Day 14 
LH Surge Days 15-28 (Luteinizing Phase). b) Regular Menstrual Cycle:  Estrogen levels peaking at Day 
14, which allows for growth of a follicle and LH surge at Day 14. Progesterone levels peak during Days 18-
22 to decrease levels of estrogen and corpus luteum. c) Menstrual Cycle under the influence of OC - 
Arrows indicates OC influence on hormone levels from Day 7-28. Progesterone suppresses estrogen levels 
and minimizes the growth of a follicle. 
 
 The follicular phase occurs from days 1-14, where the first 7 days is the onset of menses. 
During the first week, gonadotropin hormones, FSH and LH are secreted and act upon the 
follicle to stimulate growth. Specifically FSH stimulates the granulosa cells of the follicle to 
grow and LH stimulates the theca cells to hypertrophy. Granulosa cells are the part of the follicle 
that produces and secretes estrogen and theca cells are responsible for producing androgens that 
convert into estrogen in the granulosa.  Estrogen works as a feedback mechanism for the 
gonadotropins, with a small amount of estrogen the FSH and LH are reduced in secretion 
through a positive feedback mechanism; however, as the estrogen continues to be produced from 
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the granulosa cells, FSH and LH rise due to a negative feedback mechanism. Inhibin is also 
secreted from the granulosa and inhibits the rise in FSH and as estrogen starts to peak, its 
feedback on LH produces a larger rise and surge of LH mid cycle.  
 On day 14 the LH surge causes ovulation and the egg is released. The luteal phase 
is when the granulosa and theca cells of the follicle evolve into the corpus luteum.  As LH begins 
to drop it acts upon the corpus luteum to produce and secrete more progesterone, estrogen and 
inhibin. Increased progesterone levels suppress the secretion of FSH and LH.  The corpus luteum 
begins degeneration due to lower levels of LH; therefore, production of progesterone and 
estrogen also decrease. FSH and LH begin to secrete and the cycle begins once again. Natural 
occurrence of this cycle has not been show to be detrimental to bone health; however control of 
this cycle through OC use could be detrimental since circulating levels of estrogen are decreased 
which are important to bone maintenance (ESHRE Capri Workshop Group, 2010). 
 
2.4.3 Hormonal Contraceptives and Oral Contraceptives 
The term hormonal contraceptive encompasses a multitude of birth control types 
including the patch, intrauterine devices (IUD), depot medroxyprogesterone acetate (DEPO), and 
OC.  Hormone releasing IUD is placed in the uterus and releases progesterone into the body. 
Both the patch and OC provide a combination of estrogen and progesterone. The patch is placed 
on and absorbed through the skin and OC is an orally ingested tablet.  
 
2.5 Environmental Influences on Children’s Bone Accrual  
Early environmental factors such as PA and diet have been shown to have significant 
effects on bone later in life (Bailey et al., 1999) as has OC use (ESHRE Capri Workshop, 2010). 
Genetics accounts for large percent of bone mass while environmental lifestyle also contributes 
to bone mass accrual and reduction in osteoporotic diagnoses (Teegarden, Legowski, Gunther, 
McCabe &Peacock et al., 2005). 
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2.5.1 Physical Activity 
PA has been proven to have a beneficial effect on the growing and mature skeleton 
(Bailey et al., 1999). Studies have demonstrated that high impact loading of the bone increases 
bone mineral accrual over and above accrual that is associated with normal habitual activities 
(McKay et al., 2000). Impact loading activities such as running, jumping, gymnastics, and tennis 
put a muscular load on the skeleton creating a strain on the bone that increases bone 
development. Putting strain on the bone via the skeletal muscles through high impact movement 
actualizes the overload principle. The dynamic workload allows deformation of the bone and the 
strain signals for repair by bone cells (Frost, 1997).  Osteocytes within the cell matrix are 
engineered to detect the strain in the bone tissue and signal to adapt the bone tissue to increased 
levels of strain (Lanyon, 1996) through the process of modeling and remodeling. The 
mechanostat theory by Frost (1997), explains that throughout normal life, from everyday 
movement of the skeleton by skeletal muscles, there is an increase in tension and strain on the 
skeleton that results in benefits to bone mass.   
Frost (1997), also points out that estrogen plays a role in Ca storage in the bones and that 
low levels of estrogen and disuse of the muscles after menopause may be responsible for changes 
in bone maintenance. During the menstrual years levels of estrogen regulate the storage of 
calcium needed for breast-feeding. These higher levels of estrogen, in comparison to after 
menopause, promote a high level of bone modeling and remodeling. If physical activity were to 
stay consistent, when estrogen is lowered during menopause, the remodeling and modeling 
thresholds are lowered and start to reduce the amount of bone mass maintained, even with the 
same amount of strain from exercise (Frost, 1997; Lanyon, 1996). In order to maintain optimal 
bone mass, it is thought that the strain from physical activity would need to increase. It is 
believed that estrogen plays a key role in adaptation to mechanical loads (Lanyon, 1996). Lanyon 
(1996) indicates that bone losses from disuse and estrogen decreases are similar and that a higher 
load may be needed to maintain optimal levels of bone mass.  
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Bailey et al., (1999), in their 8-year longitudinal pediatric bone mineral accrual study, 
analyzed PA at bone accrual during adolescence. Dual Energy X-Ray Absorpitometry (DXA) 
was utilized to address bone parameters of the TB, LS and FN BMC. Other measurements were 
taken of anthropometry, diet and PA. Data was collected bi-annually over the 8 years. PA was 
assessed by questionnaire. Participants were divided and analyzed by levels of activity (active, 
average, inactive). Participants in the active groups had a higher peak bone mineral accrual, 
which took place in the 2 years surrounding PHV, in comparison to the inactive group. 
Specifically the active female group had a 17% greater TB BMC than those in the inactive 
group. This difference was maintained in adulthood when it was found that active group had 
greater BMC ten years after PHV (Baxter-Jones, Kontulainen, Faulkner & Bailey, 2008). 
PA is known for its benefits on the skeleton and it has been recently shown that PA doses 
increase BMC. A longitudinal study by Baxter-Jones et al., (2008) suggests that females that are 
physically active during their adolescence will have 9-10% more BMC in adulthood than those 
of the less active groups. During adolescence where peak amounts of growth are occurring, PA is 
essential to increasing BMC and to aid in gaining peak BMC levels. PA during adolescence and 
young adulthood has been shown to increase bone mass (Baxter-Jones et al., 2008; Kannus, 
1999). High impact activities such as weightlifting and gymnastics are most beneficial to 
increasing BMC during adolescence (Bailey et al., 1999). PA attribution to bone mineral accrual 
and peak bone mass is important to consider when analyzing adolescents as the difference in 
activity levels will have a confounding effect on the outcomes. It is essential for adolescents to 
increase their PA in order to gain the reward of increased bone mass and decrease the risk of 
osteoporosis.  
McKay, et al., (2000) conducted an intervention study on 144 school-aged children. The 
participants were divided into control and exercise groups. The exercise group was involved in 
an 8-month exercise program that used loading and movement exercises 3 times a week for a 
minimum of 10 minutes. DXA scans were taken of the TB, LS and FN at baseline and 
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conclusion of study.  Results of this study indicated that children aged 7 to 11 who are involved 
in jump training will have a greater increase in femoral trochanter aBMD than those who do not 
participate in such activities.  
 MacKelvie, Khan, Petit, Janssen and McKay (2003) performed a 2-year intervention study 
with 179 female participants aged 8 -12 years old. The schools were randomized into exercise 
and control groups. The exercise group participated in a circuit incorporating plyometrics and 
jumping obstacles as the physical activity intervention. The exercise group had a significantly 
higher LS and FN BMC after 2 years of the high impact exercise program in comparison to the 
control group, from baseline to completion of the trial.  
Fuchs, Bauer and Snow (2001) utilized activities of jumping from a box in order to give a 
ground reaction force of 8 times the body mass, to define safety and plausibility of this activity 
for young children and its potential benefits to bone health. Eighty-nine children participated in 
the intervention study and were randomized into jumping and control groups. The jumping group 
performed 100 jumps, three times a week from a 2 -foot tall box, while the control group 
performed light stretching exercises. After 7 months, the exercise group had a significantly 
higher LS and FN BMC than the control group. The exercise group also reported a significantly 
higher LS aBMD than the control group. Eight years after cessation of the intervention, the 
treatment group still had greater BMC (Gunter, Baxter-Jones, Mirwald, Almstedt, Fush et al., 
2008).  
 
2.5.2 Diet  
2.5.2.1 Calcium  
Dietary factors such as Ca are important to the growth and maintenance of bone. Ca is an 
essential component to build bone and is required during the adolescent growth phase of bone 
growth. Adequate Ca is needed from dietary sources in order to complement the demand by the 
cells in the bone (Bailey, 1997). Vantanparast et al., (2009) completed a longitudinal study on 
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113 girls ages 8 to 20 years, looking at Ca intake on bone mineral accrual and maintenance. This 
study demonstrated that girls from age 9 to 13 years should have a daily intake of 1116 mg of 
Ca, while those from 14 to 18 years should have 961 mg per day (Vantanparast et al., 2009.). 
The higher intake of Ca is needed in the years surrounding PHV, where there is a substantial 
increase in timing and magnitude of growth.  
Ca is a mineral that plays a primary role in growth and maintenance of bone and is the 
basis of the skeletal structure. By the age of 20, an adult female will have approximately 2200g 
of BMC; Ca comprises 32.2% of this BMC (Ellis, Shypailo, Hergenroeder, Perez & Abrams, 
1996). The recommended estimated average daily intake is 1,100 mg/d of Ca for females from 9-
18 years old and 800 mg/d of Ca for females 19-50 years of age to meet the requirements of 50% 
of the healthy population (Institute of Medicine, 2010). Essential to maintaining optimum levels 
of Ca is bone remodeling. The role of calcium in bone growth is the deposition into the osteoid 
cell, where its mineralization occurs around the osteoblasts cells and turns active osteoblasts into 
their least active form of osteocytes (Khan et al., 2001). Once resorption occurs, the Ca is 
removed from the matrix of which it is formed. The process of formation and absorption is 
directly reliant on Ca stores and is a dynamic process that takes place throughout growth and the 
maintenance periods.  
While it is known that adequate Ca intake is important to bone accrual, the question of 
whether Ca intake can conserve bone with the implementation of OC has also been addressed.  A 
study by Teegarden et al., (2005) suggested that an increase in Ca had positive impacts on total 
hip BMD and BMC and was a protective agent in OC users.  With the high impact of calcium 
intake on bone, it must be considered as a confounder when assessing bone accrual, as it is 
unknown whether the decrease in BMC is due to a change in Ca exposure or whether the OC are 
negatively impacting BMC levels. 
 
 
 20 
2.5.2.2 Vitamin D 
Vitamin D is essential in order to absorb the levels of calcium needed to maintain Ca 
homeostasis. Vitamin D plays a role in regulating levels of calcium (Khan et al., 2001). Vitamin 
D can be obtained from either sunlight or diet (Vantanparast et al., 2010) and is a regulatory 
factor in the dispersal of Ca from the bone, as well as a factor in the small intestine’s absorption 
of Ca (Khan et al., 2001).  
Since the primary source of Vitamin D is through sunlight exposure synthesis in the skin 
(Vitamin D2) (Vantanparast et al., 2010), it is essential to supplement with dietary vitamin D 
(Vitamin D2 and D3) during the winter months in geographical areas with reduced levels of 
sunlight (Vieth, Cole, Hawker, Trang & Rubin, 2001). With an insufficient intake of Vitamin D, 
ailments such as osteomalacia and rickets, or softening of the bone, will occur (Vantanparast et 
al., 2010). The recommended (estimated) average daily intake is 10 µg/d of vitamin D to meet 
the requirements of 50 % of the healthy population (Institute of Medicine, 2010). 
 
2.6 Hormonal Contraceptives and Oral Contraceptives Relationship to Bone and Fracture Risk 
Although DEPO is a widely used contraceptive, and it is one of the top three choices of 
birth control, it has been found to negatively impact bone health, (Busen, 2004; Lopez, Grimes, 
Shulz and Curtis, 2011). A study by Berenson, Rahman, Breitkopf and Bi (2008) found 
participants who used DEPO for 2 years had an approximately 6% BMD loss at the hip and 
spine. The US Food and Drug Commission have identified a 2-year limit as it is warning for 
women using DEPO as contraceptive (Berenson et al., 2008). While DEPO has been found to 
result in bone loss, the effect of other forms of OC use during adolescence and young adulthood 
remains unclear. 
OC are the most widely used type of birth control and is the number one choice amongst 
young women under 30 years of age in the United States (Scholes, Ichikawa, LaCroix, Spangler, 
Beasley et al., 2010). OC, which are primarily designed to prevent pregnancy, have a wide 
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variety of uses. For example, in adolescence and adulthood OC are prescribed as an acne 
medication.  OC are also prescribed to regulate menstruation and to increase estrogen in women 
with oligio-amenorrhea or polycystic ovarian syndrome.  It is important to understand the effect 
of OC use on the menstrual cycle in order to investigate its effect on bone, so to prevent usage 
that may be a cause of low bone density and osteoporotic conditions. 
OC are available in both combinations of estrogen and progesterone, and progesterone 
only.  OC deliver a synthetic form of estrogen and progestin with the dose of progestin being 
high enough to suppress endogenous estrogen production. OC are administered daily over a 28-
day cycle. With estrogen suppressed, the feedback mechanism in the menstrual cycle, to release 
FSH and LH is hindered and the follicle will not grow. This inhibits further estrogen and 
progesterone production and secretion from a growing follicle.  The constant level of 
progesterone throughout the cycle inhibits the egg from implanting. FSH and LH stay at the 
same low level throughout the 28 days. For 7 out of the 28-day cycle, a placebo or no pill is 
administered and progestin levels decline and menses occurs. After 7 days of placebo, the next 
cycle of OC are initiated. 
 Lopez et al., (2011) provided a meta-analysis of the literature examining the impact of 
OC use on bone.  The assessment of 16 trials indicated a gap in longitudinal studies, fracture risk 
assessments and consistency in study designs. Injectable (DEPO), combination OC (estrogen and 
progesterone), progesterone only OC, and implant contraceptives were assessed. Eight of these 
trials compared between OC formulations on bone parameters (Endrikat, Mih, Dusterberg, Land, 
Gerlinger et al., 2004; Hartard, Kleinmond, Luppa, Zelger, Egger et al., 2006; Rad, Kluft, de 
Kam, Meijer, Cohen et al., 2011; Paoletti, Orru, Floris, Mannias, Vacca et al., 2000; Nappi, Di 
Spiezo Sard, Acunzo, Bifulco, Tommaselli et al., 2003; Berenson, Radecki, Grady, Rickert, & 
Thomas, 2001; Nappi,  Di Spiezo Sardo, Greco, Tommaselli, Giordona et al., 2005; Gargano, 
Massaro, Morra, Formisano, Di Carlo et al., 2008).  Two of the studies compared OC 
formulations against a placebo and one study compared hormone versus no hormone 
 22 
contraceptive methods. DEPO was found to negatively affect bone health if used without an 
estrogen supplement in two trials (Lopez et al., 2011). Combination OC trials indicated there 
may be a benefit to BMD; however, these trials were not conducted in comparison to a placebo 
(Lopez et al., 2011). Lopez et al., (2011) assessed the risk of bias in these studies; however they 
were not reviewed for heterogeneity with meta-analysis due to the varying types of interventions. 
From this review it was noted that fracture risk was not assessed in any of the randomized 
control trials (RCT) studies, yet BMD was assessed as an indicator of bone health. Considering 
fracture-risk was not assessed as an outcome, the applicability of the evidence highlighted the 
need for longer studies for assessment in this area. It was also found that most of the studies that 
were reviewed had a greater than 20% loss of participants, a factor which would increase bias 
risk.  
Bitzer and Simon’s, (2011) review of hormonal contraceptives indicated that some 
studies had found combination OC negatively affected BMD but several studies indicated that 
OC with 30µg ethynilestradiol did not see a subsequent loss in BMD in the maturing skeleton 
(Llyod, Taylor & Lin, 2000; Beksinska, Kleinschmidt & Smit, 2009; Cromer, Stager & Bonny, 
2004). However, the lower dose of 20µg ethynilestradiol does not support optimal bone mineral 
accrual during adolescence (Cromer, Stager & Bonny, 2004; Bitzer & Simon, 2011).  
 In the 1996/1997 Statistics Canada Health reported a total of 18% of the population at all 
ages, was using OC (Wilkins, Johansen, Beaudet & Neutel, 2000). Of females between 15-19 
years of age 27% were users. It was also shown that 41 % of 20 -24 year olds used OC, and 33% 
of 25-29 year olds using OC. Even though less used after the age of 30 there was still a 19% user 
rate from 30-34 years of age (Wilkins et al., 2000). These statistics indicate that users potentially 
could be using OC for up to and over 20 years and therefore, may be exposed to extended 
periods of low estrogen levels, which could negatively impact bone mass. This highlights the 
importance of longitudinal studies to address the long-term effects of OC usage on bone health, 
especially since more females are utilizing OC throughout adolescence and young adulthood.  
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A 2-year cross-sectional analysis by Scholes et al., (2010) assessed over 600 adolescent 
and adult female OC users, aged 14 to 18 and 19 to 30 respectively. In this study mean duration 
of use was 9 months for adolescent users and 1 year for young adult users.  While there was no 
impact on aBMD noted during adolescence between users and non-users, the adult females 
showed a reduced aBMD. Further analysis demonstrated that, as duration of use increased, 
aBMD decreased. This study indicates that duration of use may impact aBMD in females, and 
highlights the need to assess this impact longitudinally. 
 A 5-year study by Polatti, Peroti, Filippa, Gallina and Nappi, (1995) showed young 
females between the ages of 19-22, who did not use OC had an approximate 8% increase in 
BMD from pre to post test dates, in comparison to those who used OC. BMD data was collected 
and examined every year, and non-users showed a significant increase in BMD over the test 
period, while there were no significant changes observed in the users group. It is important to 
consider the long-term effects of taking OC and their association with duration of use as a 
preventative measure for osteoporosis. Studies that choose to look at BMD and BMC over a 
short period of time may be missing the impact or changes in bone parameters that may occur 
over the longer period of time, for instance the use of a pharmalogical agent such as OC. It 
should be cautioned that a one year study, may show an increase, and a positive association with 
OC use, while in the next few years a decrease in bone mass might actually be occurring. 
 
2.7 Concerns with Oral Contraceptive Use 
Age at onset of HC use is gradually decreasing. While the primary medical use of HC is 
to prevent unplanned pregnancies, other medical conditions often rely on similar hormone 
therapy as part of the ongoing treatment. For example, OC is the first prescribed method of 
controlling irregular menstrual function (Hartard, Kleinmond, Kirchbichler, Jeschke, Wiseman et 
al., 2004), including persons diagnosed with oligomenorrhea and polycystic ovarian syndrome. 
OC is also often prescribed as an acne medication. It is not unusual therefore to see OC use 
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beginning as young as 12 years old (Rome, Ziegler, Secic, Bonny, Stager et al., 2004), the age 
coinciding with average PHV in young females. During this time of peak growth, the influences 
of estrogen depression may have a significant impact on bone accrual.  
 In the last 30 years, estrogen levels in OC have been reduced due to health risks. With the 
reduction of endogenous estrogen in the cycle due to the onset of OC use, and low-estrogen pills, 
the overall circulation levels of estrogen are compromised. Estrogen is at its highest at the 14th 
day of the cycle in order to induce an LH surge and release an egg; however, OC suppress 
estrogen at this time resulting in very low circulation levels. Therefore the question arises: does 
this lower dose of estrogen and lower circulation levels due to estrogen suppression provide 
enough estrogen for optimal bone turnover (Cromer et al., 2008). 
Liu and Lebrun (2006) conducted a systematic review of 75 articles. Quality of evidence 
was based on the Oxford Centre for Evidence-based Medicine levels. Under the healthy 
population category, 10 studies indicated a positive effect of OC use on bone (7 cross-sectional, 
3 cohort studies). Twenty-nine studies found no effect of OC use on bone (4 RCT, 9 cohort, 15 
cross-sectional), while 7 studies (4 cohort and 3 cross-sectional) reported a negative effect of OC 
use on bone health.  This review concluded that there were positive effects of OC on populations 
of peri-menopausal and oligio-amenorhhea women. Both these populations suffer from a 
decreased amount of estrogen, and its believed that the supplemental estrogen improved their 
circulating levels and in turn optimized their bone mass. However, in healthy pre-menopausal 
women the research findings are less consistent. The conclusions of this review may be 
influenced by the differences across the study designs and varying quality of evidence found, 
from individual cohort study to case series (Levels 2b to 4) (Polatti et al., 1995; Burr, 
Yoshikawa, Teegarden, Lyle, McCabe et al., 2000; Cromer et al., 2004, Hartard et al., 2004; 
Rome et al., 2004; Hartard, Bottermann, Bartenstein, Jeschke & Schwaiger, 1997) which reflect 
a lack of higher levels of evidence. Each study assessed indicated a difference in time-line of 
study, age groups assessed and type of study (RCT, cohort, cross sectional). The need for 
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consistency in testing to indicate the impact of OC on bone needs to be considered. Longitudinal 
design is needed to assess the impact of: lifetime use, duration of use and initiation of use.        
Table 2.7 summarizes the quality of evidence assessment for the reviewed literature 
pertaining to the effects of OC use on bone health. Assessment of evidence was based upon the 
U.S Preventative Services Task Force (2009), and is defined as follows, from strongest to 
weakest: 1) meta-analysis/systematic review, 2) RCT, 3) quasi-experimental, 4) controlled 
observational, 5) observational studies with no controls and 6) expert opinion. Further 
information regarding quality of evidence can be found from Lopez et al., 2011; Bitzer and 
Simon, 2011; and Liu and Lebrun, 2006.                                                                                                           
 
Table 2.7 Literature Review Quality of Evidence  
Article  Quality of 
Evidence 
Level 
OC Effect 
on Bone 
Study Design Age 
Group 
(yrs) 
Length of 
Study 
N 
Lopez 
2011 
1 - Meta-analysis - - - 
Bitzer  
2011 
1 - Review - - - 
Scholes 
2010 
3 Negative Cross-
sectional 
14-30 - 606 
Polatti 
1995 
3 Negative Cohort 19-22 5 years 200 
Hartard 
2004 
3 Negative Cross-
sectional 
18-35 - 69 
Rome  
2004 
3 No effect Cohort 12-18 1 year 370 
Liu  
2006 
1 10 Positive 
29 No effect 
7   Negative 
Systematic-
Review 
- - - 
Nappi 
2005 
2 No effect RCT 22-34 1 year 71 
Ruffing 
2007 
3 Negative Cross-
sectional 
  135 
Burr 
2000 
3 Negative Cohort 18-31 2 years 123 
Berenson 
2008 
3 No effect Cohort 16-33 3 years 703 
Cromer 
2008 
3 Negative Cohort 12-18 2 years 433 
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The study by Nappi et al., (2005) examined two different low-dose OC combinations 
over a 12-month period on women ages 22-34 years.  The 21-day OC formulations consisted of 
30-µg ethinyl/estradiol with varied amounts of synthetic progesterone. Combination 1 added 3 
mg drospirenone and combination 2 added 30 µg of gestodene.   Both combinations showed 
beneficial effects on bone turnover in the female users groups versus the control group.  Also, 
there were no significant differences in spinal BMD between the two users groups and control 
group from pre-test to post test values (Nappi et al., 2005). In contrast, a 4-year study by Ruffing 
et al., (2007), showed a reduction in BMD and BMC in college-aged female cadets who were 
OC users, with users defined as having used OC for 3 months or more in their lifetime. A 2-year 
study by Burr et al., (2000), similarly showed that OC use in females aged 18-31, may be 
associated with a reduced increase of bone mass at the femoral neck (FN).  The retrospective 
study of Hartard et al., (1997) on 128 women from 20-35 years of age also showed that OC use 
masked the beneficial effect of long-term exercise on bone mass. 
The differences in the literature not only highlights the need to further assess OC impact 
on bone, but also highlight the lack of a longitudinal approach since these studies so far have 
looked at relatively short-term gains and losses of bone. The inconsistent study designs have 
included a broad range of chronological and maturational ages (i.e. 12 to 35 years) and have 
divided the adolescent and adult subgroups differently. Grouping the adolescents by terms of 
maturation as well as adults by the mature skeleton when addressing bone health is prudent in 
order to assess the differences OC use has on bone health and maintains consistency among 
studies. Not only does OC use still need to be addressed, but also the duration of use and timing 
of initiation in order to evaluate the implications on bone health during the growing and mature 
phases of bone formation and resorption.  Long-term studies are needed to address the gaps in 
the literature and provide clarity as to the influence of OC on bone development, in order to 
implement the right preventative strategies for osteoporosis in adolescence and adult life. 
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2.8 Longitudinal Versus Cross-Sectional Studies 
Longitudinal studies are the process of following a selection of same-aged individuals 
and collecting data serially in order to see developmental patterns (Tanner, 1978). The advantage 
of this process is that there is no variability between children or ages, as the same child is re-
analyzed each year. However, this type of study is costly and demands a larger time 
commitment. Cross-sectional studies take one measurement at one period and make a prediction 
based on the outcomes of the sample population. It generalizes the growth of a child over 5 years 
based on 5 different children at different ages. The positive of this, is data can be collected and 
analyzed quickly (Tanner, 1978). The limitation of a cross-sectional design is the assumption 
that children grow at the same time and magnitude (Cromer, 2003).  Mixed longitudinal studies 
have an intake of several age groups over a few years, this allows for a range of data from 
several individuals over a shorter period of time with the age range of a longer period. Example: 
Over a span of 3 years, take in cohorts of children aged 8-12, this allows for a data set of ages 8 
to 15 years growth and development within a 3-year time span (Tanner, 1978). With a mixed 
longitudinal study, individual growth patterns can be acquired and used in order to assess 
differences in skeletal growth.  
Considering the 6-year timeline of 50% skeletal growth from 12-18 years (Cromer et al., 
2008) and the lifestyle influences, such as pharmacological agents, the timing of initiation of OC 
use with respect to maturation needs to be examined. Berenson et al., (2008) performed a 3-year 
study using 16 to 33 year old participants using OC and showed an increase in the spine BMD in 
the first 12 months, then a gradual decrease. In contrast, a study by Cromer et al., (2008) looked 
at participants 12-18 years of age and indicated a majority decreased their spine BMD in the first 
year of OC use. Discrepancy between the two studies may be due to the lack of consideration 
ascribed to the individual growth patterns. As stated previously, adolescents do not mature at the 
same rate; therefore, age of maturation (indexed by example PHV) should be used when 
comparing adolescent OC users. Those participants showing an increase in bone, may in fact be 
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having a detriment in bone accrual related to OC use but are being recorded as attaining bone, 
due to the accrual that is occurring as a consequence of their natural growth spurt. OC use in 
relation to PHV may provide further insight into the impact of OC use on bone accrual.  
 
2.9 Summary of Literature Review 
Osteoporosis is a problem that still needs investigation in order to find the best 
preventative strategies from allowing this disease to occur. Antecedents such as PA and diet in 
childhood are responsible for up to 45% of skeletal growth. PA, and diet are important factors for 
bone accrual and need to be accounted for when studying bone growth. Recently, research 
focusing on the impact of OC use on bone has become more prevalent, thus far however the 
findings have been equivocal. This leads to the current research questions: Does oral 
contraceptive use have an effect on bone mineral content with respect to duration of use and 
initial timing of use? The use of longitudinal assessment is imperative as it allows the impact of 
OC use on bone from adolescence through adulthood to be examined. This type of assessment 
also extends the look at the effects of duration of use in conjunction with the normative duration 
of OC use by women.  
Hence it was the purpose of this study was to assess the long-term effects of OC use 
during adolescence and young adulthood on subsequent bone mineral accrual. It is hypothesized 
that non–users of OC will have greater TB, LS, and FN BMC in comparison to OC users. It is 
also hypothesized that those that have initiated OC during adolescence will have a significant 
decrease in bone mineral accrual in comparison to the to those that initiate 6 years post peak 
height velocity (PPHV) and non-users. It is also hypothesized that those who use OC for a 
greater length of time will have significantly lower BMC at the TB, LS and FN than those that 
have used for lesser time and non-users. 
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3.0 METHODS 
 
3.1 Study Design 
The University of Saskatchewan’s (U of S) Pediatric Bone Mineral Accrual Study 
(BMAS) is a mixed-longitudinal cohort design that was initiated in 1991. The purpose of the 
study was to assess bone growth from childhood into adulthood and investigate environmental 
influences such as physical activity and diet on bone accrual (Bailey, 1997). The study began 
with eight chronological age clusters (entry age 8 to 15 years) in 1991, with additional 
recruitments in 1992, and 1993. Data was collected until 1997/98, and was resumed again from 
2002 to 2010. This design allowed for a 22-year developmental pattern from 8 to 30 years of age 
(Table 3.1) to be measured in 11 years.   
 
 
 
Table 3.1-Number of subjects by age group and year of test. 
 
 
 
Table Description: The total number of participants from 1991- 2007. Male participants (n) are indicated 
per year and age group, followed by the number of female participants (n) in brackets indicated for each 
year and age group for each cohort of the study. 1991, 1992 and 1993 were intake years for the study.   
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3.2 Participants 
 
BMAS participants were recruited from two elementary schools located in Saskatoon, 
Saskatchewan (population 200,000). In 1991 a total of 228 students (113 boys and 115 girls) 
provided written consent to participate and 220 children were DXA scanned. From 2002 – 2007 
data was collected on 169 returning participants (85 males and 84 females) (Table 3.1). From 
2009 to 2010, 100 participants returned for measurement (35 males and 65 females not shown in 
table).  
For the present analysis, female participants (n=121) were drawn from BMAS. To be 
included in the study, subjects were required to have had three DXA measures, with at least 2 
occurring in childhood. Ethics was obtained through the U of S Biomedical Research Ethics 
Board (Appendix A). Testing took place at the College of Kinesiology bone growth and 
anthropometry laboratories at the U of S. Prior to testing the subjects were informed of the 
testing protocols and informed consent was obtained (Appendix B). During childhood and 
adolescence, assent was collected from the subjects and consent from their parents. At any point 
subjects were allowed to withdraw from the study, and could choose to not participate in testing 
components.  
 Subjects that were absent due to pregnancy at time of annual data collection were still 
included at other time points. Only subjects using the oral contraceptive pills (n=48), and 
contraceptive patches (n=1) were included in this study. 
 
3.3 Anthropometric Measurements 
Height, sitting height, and weight were assessed bi-annually from 1991 to 1997, and 
annually for the remainder of the study. Participants wore light clothing for the anthropometric 
measurements.  Height and sitting height measurements were taken to the nearest 0.01 mm using 
a stadiometer (Holtain Ltd, Crymych, Dyfed, UK). Body mass was measured to the nearest 0.1 
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kg using a standard physician scale (Toleda Scale Company, Windsor, Ontario, Model # 2830). 
A certified exercise physiologist performed all measures.  
 
3.4 Chronological Age, Biological Age and Age of Menstruation 
Chronological age was calculated from the decimal age at test date subtracting the 
decimal age at birth date, for each participant. Age categories were scaled into yearly groups 
from 8 to 33 years of age.  For example, those with the decimal age of 10.50-11.49 were 
categorized as age 11.  
Biological Age (BA), a measure of maturation, was defined by alignment with age of 
PHV. PHV was determined by measuring the acceleration of the velocity curve of statural 
growth (cm/year), obtained through serial measures of standing height (Malina et al., 2004) 
during the child and adolescence periods.  PHV is calculated using longitudinal data of annual 
stature measurements. The process includes fitting a cubic spline to the velocity values of each 
child per year (Bailey et al., 1999).  Therefore, peak linear growth was derived from the result of 
chronological age at test minus chronological age at PHV (Baxter Jones et al., 2008). Biological 
age at test was calculated by the decimal age at the test date, minus the decimal age at PHV. 
First date of menstruation was collected retrospectively as the subjects participated every 
six months, and researchers assessed time of menstruation between the two testing dates in 
which menses occurred. Actual age of first menstruation was determined by subtracting cycles of 
28 days from the participant’s most current menses. For those who attained menarche between 
test dates, the date was recorded retrospectively. 
 
3.5 Body Composition 
DXA (Hologic 2000 QDR, Hologic, Waltham, MA), was utilized to assess BMC grams 
(g), aBMD grams per centimeter squared (g/cm2) and body fat percentage. This method involves 
the passage of high and low photon beams which attenuate through the body, fat tissues and bone 
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in order to give an estimate of the composition of soft tissue and bone mineral in the body.  The 
DXA uses two x-ray beams, which exposes the participant to radiation; however, DXA is used 
due to its low levels of radiation and exposure risk. DXA has equivalent radiation to regular 
daily life of five days (Malina et al., 2004). A licensed X-Ray technician performed all DXA 
measurements on the participants.  BMC and aBMD were taken at the TB, anterior-posterior LS 
(L1-L4) and FN sites. All participants were instructed to wear light clothing, free of any metal 
for the DXA scan. The coefficient of variation (CV) for Hologic 2000 for TB, LS and FN and LS 
BMC are 0.60, 0.61 and 0.91 respectively and TB, LS, FN aBMD are 0.51, 0.88 and 0.90 
respectively (Faulkner, Forwood, Beck, Mafukidze, Russell et al., 2003). The new DXA Hologic 
2000 implemented in 2008. BMC and aBMD CV are 0.5% TB, 0.5% LS and 0.7% FN (Cornish 
& Chilibeck, 2009). 
 For the TB scan, participants were asked to lie on their back in a horizontal position on 
the mat in the DXA machine. In order to prevent the superior aspect of the scapula and the 
mandible from overlapping, the subject’s head was positioned with shoulders depressed, chin 
raised and arms in anatomical position (Erlandson, 2007). The feet were aligned so they rotated 
internally and any participants unable to hold their feet in this position had their feet taped for 
immobilization. This position eliminates the tibia and fibula overlap in the scan (Erlandson, 
2007). For the LS scan, participants were aligned in order to raise the ribs away from the lumbar 
spine, by holding their hands behind their head. To reduce the lumbar curve and place the spine 
in contact with the mat, a box was placed under the participant’s lower legs. The FN scans, were 
taken with the participant laid supine with the foot on the side of the hip being scanned inverted 
approximately 30 degrees. This position was held with a nylon belt and a positioning wedge 
(Erlandson, 2007). The arm of the subject was positioned outside the area of the scan. 
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3.6 Hormonal Contraceptive Therapies 
Participants filled out a lifestyle questionnaire (Appendix C) that assessed HC use. HC 
use was assessed prospectively and retrospectively, as these questions were used in the study 
from 2002-2010 only.   HC specific questions were: Are you currently using oral contraceptives? 
What type of oral contraceptives do you use? How long have you been using oral 
contraceptives?  
 Age of first HC use and duration of use of HC use was calculated retrospectively by dates 
of last menstruation. The type(s) and brand(s) of HC used, and duration of use were each 
determined from information provided by the participants. 
 
3.7 Diet and Physical Activity 
Participants filled out a 24-hour Food Recall (24-HFR) questionnaire (Appendix D), to 
assess Ca and vitamin D intake. The 24-HFR questionnaires ask participants to record all the 
food, beverages, vitamins and supplements they consumed the previous day. A visual aid was 
available to determine portion sizes for each item the participant listed on the 24-HFR. The 
correlation coefficient 0.80 for 24-HFR is based on 7 recalls per year (Whiting & Shrestha, 
1993). Physical Activity was assessed using the Physical Activity Questionnaires for children 
(PAQ-C), for adolescents (PAQ-A) and adults (PAQ-AD) (PAQ-AD see Appendix E). This 
questionnaire determines the level of physical activity a subject participates in, in a typical week. 
Example: This includes activities that make you sweat, make your legs feel tired or make you 
breathe hard. In the last 7 days during the morning, how often were you active (none, 1 time, 2 to 
3 times, 4 to 5 times, 6 to 7 times last week)? The re-test reliability of PAQ-C in females is r = 
0.82. The peer-comparison activity rating is r = 0.73 for the PAQ-A and the PAQ-AD correlation 
is r = 0.53 to 0.64 (Copeland, Kowalski, Donen, & Tremblay, 2005).  
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3.8 Data Analysis 
Data between non-users and OC users were compared using analysis of variance 
(ANOVA) to check for differences between descriptive characteristics of height, lean mass, PA, 
vitamin D and Ca. Data were analyzed to assess the effect of: 1) OC use, 2) Duration of OC use, 
and 3) Time Frame of initiation of OC use on aBMD and BMC at the TB, LS and FN. Subjects 
were grouped into OC users (n = 49) and non-users (n= 72). Users were defined as those that 
used OC for one or more years. The OC users group was sub-grouped by years of OC use; Group 
a: 1 to 5 years, Group b: 5 to 10 years, and Group c: 10 plus years. They were also grouped in 
relation to initiation of use. Group i: non-users, Group ii: 1 to 6 years post PHV, and Group iii: 6 
plus years post PHV. The users of the OC initiation groups were divided into Group i to simulate 
the 6 years adolescent growth period after PHV, typically from 12 to 18 years of age, based on 
timing of maturation. Group ii simulates the mature adult skeleton and adolescent growth has 
stopped after the age of 18. These two groups are divided by adolescent and adult OC initiation.  
Analysis of covariance (ANCOVA) was used to analyze group differences in 
demographic characteristics (covariates: physical activity and diet) prior to analysis of bone 
parameters. ANCOVA was then used to analyze group difference amongst the groups. Post hoc 
tests were used to determine where the differences occurred between the groups. BMC 
comparisons were adjusted for covariates (height, lean mass, PA, vitamin D and Ca) for each site 
(TB, LS, FN). Each OC use model was analyzed separately for aBMD and BMC at each site 
(TB, LS, FN) at each time point for both chronological age and BA. Statistical difference was 
assessed between groups using Statistical Analysis Software (SPSS version 18, SPSS Inc., 
Chicago, IL).  Level of significance was p < 0.05.    
Limitations of using ANCOVA in this study are the increase in occurrence of a Type 1 
error, meaning that a difference may be shown when there is not one.  MANCOVA cannot be 
used to reduce this error in this study, as a complete data set from 8 to 30 years of age would be 
needed.  The design of this study allows for participants to miss some age points and therefore 
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group numbers change at each time point.  In order to have as many participants at each group 
for a population mean, ANCOVA is used to assess the differences at each age, with different 
group numbers.  Another assumption of ANCOVA is the normality of distribution of the 
population. The sample number at the 30-year mark is considerably smaller than at 8 to 10 years 
of age. The assumption is these 5 individuals at 30 represent the population. Another limitation 
of this statistical analysis is the homogeneity of variance, meaning the variance is equal across 
the sample. Once again the low numbers at the age of 30 may contribute to an indiscretion of this 
assumption.  
 
 
4.0 RESULTS 
4.1 Descriptive Data 
 
 Table 4.1 lists the demographic characteristics of the subjects. When aligned by BA, 
there was a difference in vitamin D, PA score and calcium intake at -1.00, 11.00, 15.00 and 20 
between users and non-users groups. Therefore, during analysis of users versus non-users, 
physical activity, calcium, vitamin D, height and lean mass were used as covariates. 
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Table 4.1- Characteristics of Non-users and Oral Contraceptive Users  
 Non-Users Oral Contraceptive Users 
Biol. 
Age 
n Height 
(cm) 
Lean 
Mass 
(g) 
PA 
Score 
Vitamin 
D 
(iu) 
Calcium 
(mg) 
n Height 
(cm) 
Lean 
Mass 
(g) 
PA 
Score 
Vitamin 
D 
(iu) 
Calcium 
(mg) 
0 33 153.9 3.0 3.1 260.2 1028.1 32 154.6 3.0 3.0 318.6 1081.4 
1 36 161.7 3.5 2.8 223.7 968.3 40 160.0 3.4 2.9 258.8 1012.8 
2 38 163.5 3.7 2.7 194.1 861.8 13 163.7 3.6 2.8 251.2 1013.1 
3 44 165.4 3.7 2.6 227.8 875.6 39 164.8 3.7 2.7 220.0 943.1 
4 30 164.7 3.8 2.4 185.9 802.4 31 166.3 3.9 2.6 175.3 175.3 
5 21 164.9 3.7 2.3 221.0 836.4 30 166.4 3.9 2.2 239.2 923.1 
6 14 164.7 3.9 2.1 215.7 868.2 24 166.4 3.9 2.2 213.9 1042.8 
7 11 169.9 4.0 2.0 160.7 779.8 22 167.0 4.0 2.0 160.7 979.3 
8 10 170.4 4.2 2.3 190.2 847.1 13 166.5 4.0 2.3 216.3 948.3 
9 8 163.7 3.9 2.2 165.5 896.5 11 166.8 3.9 2.3 165.6 872.4 
10 8 163.3 3.9 2.2 174.7 687.7 14 167.6 3.9 2.2 155.3 687.7 
11 9 163.1 3.7 2.8* 157,1 851.4 19 166.9 4.0 2.0* 269.7 975.2 
12 8 166.6 4.1 2.3 239.9 1020.3 24 165.5 4.0 2.2 216.6 870.9 
13 13 166.6 4.1 2.5 156.1 756.2 30 167.5 4.2 2.24 237.0 982.3 
14 7 166.8 4.0 2.1 213.7 902.4 23 165.7 4.1 2.2 204.4 898.8 
15 12 167.0 4.3 2.4 146.8* 800.0 16 165.8 4.2 2.1 278.5* 1040.2 
16 10 167.6 4.4 2.6 228.4 957.8 12 164.3 4.1 2.1 230.5 1126.2 
17 8 164.6 4.1 2.5 157.7 644.6 5 163.7 4.0 1.8 170.7 956.5 
18 4 168.6 4.4 2.4 146.4 737.1 8 165.6 4.7 2.0 232.8 1029.1 
19 6 168.6 4.4 2.1 135.0 982.3 8 166.7 4.6 2.4 454.7 1277.5 
20 5 166.9 5.0 1.9 107.2 473.4* 6 163.2 4.5 2.1 264.3 1416.1* 
 
 
 Figure Description: Preliminary comparison between non-users and oral contraceptive users of height, lean 
 mass, physical activity (PA), vitamin D and calcium. Biological age from 0 to 20 represents approximately 
 12-32 years of age. PA score is rated from 1 to 5 (1=inactive, 5=active). Data are expressed as a mean. 
 *Significant values presented in  bold between non-users and oral contraceptive users, p. <0.05. 
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4.2 Analysis of Group Differences in Bone Mineral Density 
 
4.2.1 Non-users vs. OC Users 
 
 There was a significant difference between groups in adjusted TB BMC at the BA of 20 
years. The non-users had greater mean TB BMC than the users (p < 0.05, non-users: 2576.571 
+/- SEM 50.193; users: 2226.491 +/- SEM 44.216). There were no significant differences at any 
other time points between users and non-users. As well, there were no significant differences 
found at the total LS BMC.  There were no other significant differences at the FN BMC between 
users groups. See Figure 4.2. 
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Figure 4.2- Total Body, Lumbar Spine and Femoral Neck Bone Mineral Content Between  
        Non-users and Oral Contraceptive Users
 Figure Description: Comparison of a) Total body, b) Lumbar Spine, c) Femoral Neck bone mineral content 
 (BMC) adjusted for covariates (height, lean mass, physical activity, vitamin D and calcium) between non-
 users and oral contraceptive users. X-axis is biological age aligned by peak height velocity. Data are 
 expressed as mean +/- SEM. * Significant differences between groups p < 0.05 
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4.2.2 Duration of Use 
There was no significant difference between user groups at any time point at TB, LS or FN for 
duration of use analysis.  
Table 4.2- Comparison Between Non-users and Users Across Duration of  
      Oral Contraceptive Use in Young Adulthood 
 Non User User 1-5 yrs User 6-10 yrs User 10+ yrs 
n 25 8 18 13 
Total Body 
BMC 
2258.46 2343.42 2302.52 2200.91 
Lumbar Spine 
BMC 
61.65 63.81 60.75 60.10 
Femoral Neck 
BMC 
4.36 7.77 4.40 4.23 
Total Body 
aBMD 
1.10 1.14 1.11 1.11 
Lumbar Spine 
aBMD 
1.04 1.05 1.023 1.04 
Femoral Neck 
aBMD 
0.85 0.88 0.85 0.86 
 
Table Description: Comparison between non-users and oral contraceptive users (OC) duration of use (1-5 
years, 6-10 years, 10+ years) adjusted for covariates (height, lean mass, physical activity, vitamin D and 
calcium) bone mineral content (BMC) and areal bone mineral density (aBMD). BMC expressed as g/cm2 
and aBMD as g/cm2. Number of participants in each group (n).  Data are expressed as mean. No significant 
differences were found between groups p  < 0.05. 
 
 
4.2.3 Initiation of Use 
 Results from the ANCOVA indicated at BA 20, non-users had significantly greater TB 
BMC than those who initiated OC use 7+ years PPHV.  At the BA 7 years there was a significant 
difference between users groups, where those who initiated OC use 1-6 years PPHV had greater 
LS BMC than those who initiated 7+ years. There was no significant difference between groups 
at the LS or FN for adjusted BMC. There was no significant difference between groups at the FN 
for mean adjusted BMC at any time point. 
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Table 4.3 – Longitudinal Comparison of Non-users and Age of Initiation of  
        Oral Contraceptive Use  
 Non 
User 
   User 1-6 yr 
PPHV 
   User 7+ 
yr PPHV 
   
Time from 
PHV 
PHV 
0.00 
PPHV 
7.00 
PPHV 
18.00 
PPHV 
20.00 
PHV 
0.00 
PPHV 7.00 PPHV 
18.00 
PPHV 
20.00 
PHV 
0.00 
PPHV 7.00 PPHV 
18.00 
PPHV 
20.00 
Approximate 
Chronological 
Age 
12 19 30 32 12 19 30 32 12 19 30 32 
N 33 11 4 5 14 12 1 3 18 10 7 3 
Total Body 
BMC 
1296.9 2095.8 2351.5 2599.6 * 1319.2 2206.1 2219.6 2178.8 1354.1 2073.5 2355.9 2235.8 * 
Lumbar Spine 
BMC 
32.2 56.4 51.7 59.6 33.8 63.3 * 86.7 67.3 33.5 53.7 * 62.5 57.5 
Femoral Neck 
BMC 
3.3 4.4 5.0 5.1 3.2 4.4 4.8 3.5 3.2 4.0 4.6 4.5 
 
Table Description:  Comparison between non-users and initiation of oral contraceptive (OC) users (post 
peak height velocity (PPHV) 1-6 years, PPHV 7+ years) bone mineral content BMC adjusted for covariates 
(height, lean mass, physical activity, vitamin D and calcium). Biological age aligned by peak height 
velocity (PHV). BMC expressed as g/cm.  Data are expressed as mean. * Significant differences between 
groups p < 0.05 
 
 
 
 
5.0 DISCUSSION 
There were three main findings of this study. There was a significant difference between 
non-users and OC users at the BA 20, approximately 32 years of age. Those that initiated OC use 
in adulthood (7+ years PPHV) had significantly less TB BMC than those who had never used 
OC. The group that initiated OC use during adolescence (1-6 years PPHV) had greater LS BMC 
at BA 7, approximately 19 years of age in comparison to the group that initiated OC use in 
adulthood.  Up until this point, longitudinal studies exploring the impact of OC use have been 
limited to 3 to 5 years (Berenson et al., 2008; Pollatti et al., 1995). In addition, none of these 
studies have incorporated maturational status into the skeletal assessments that were made 
(Berenson et al., 2008), which does not account for individual timing and growth patterns when 
comparing across participants and intervention groups. Without a careful look at the growth and 
development of persons prior to and after PHV (Tanner, 1978), it is impossible to know whether 
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the change in BMC is due to the natural growth pattern or whether there is causation from OC 
use. By incorporating the individual growth patterns of each participant in the data analysis this 
study has overcome this limitation and has provided a stronger analysis of the impact of OC use 
on skeletal attributes.  
 
5.1 Non-users versus OC users 
It was hypothesized that users of OC would have less TB, LS and FN BMC than non-
users. The non-users showed a significant increase of TB BMC at the BA of 20, which 
corresponds to approximately 32 years of age. There were no significant differences at any other 
time point. The OC users significantly lower TB BMC at 32 years of age may indicate a decline 
in accrued bone, due to the hormone alterations that only become a detriment to bone later in 
life. The significantly lower TB BMC may be due to the natural decline in bone mass that starts 
at the end of the third decade of life (Frost, 1997), which would need to be further assessed with 
the age groups over 30 to 40. Typically the LS is the final skeletal site to complete peak bone 
mass accrual, while the FN peaks earlier. A study by Baxter-Jones et al., (2011) indicated that 
TB peak bone mass was achieved at approximately 19 years of age, while peak LS was at age 17 
years and FN at age 15, so it would be assumed that a natural decline in BMC would show at the 
LS or FN earlier; however, there were no significant differences at any other site tested. This 
lower TB BMC could be because of the natural decline of BMC after the age of 30 and while 
one might expect specific site differences based on the work of Baxter-Jones et al., (2011) this 
was not evident in this study.  Lack of site-specific difference may be due to the age of the 
participants, where these specific declinations in BMC may be seen later in life when bone 
mineral begins to rapidly decline.  
The amounts of TB BMC in both groups are within the normal range. Moolgard, 
Thomsen, Prentice, Cole and Michaelsen (1997) indicates the average TB BMC at 20 years of 
age is approximately 2250 g. Comparatively, the non-users of this study at 20 years of age had 
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2211 g of TB BMC and the users had 2108 g. By the age of 32, the non-users had 2576 g and the 
users had 2226 g of TB BMC, where the non-users had significantly more TB BMC, however 
the users were still within the normative range for TB BMC. Even though both groups had 
normative values for TB BMC, future TB BMC may be at risk if the rate of loss is higher due to 
the hormonal influences from OC use, than the natural loss that occurs after the age of 30. Since 
the largest drop off of BMC is during the time of menopause, due to a reduction in estrogen 
levels (Khosla, 2010), it is important to continue addressing the OC use impact after 30 years of 
age up until the time of menopause in order to further assess whether OC use has an detrimental 
impact on rate of bone loss. Further assessment through longitudinal studies may be able to 
address the question of whether the estrogen levels under the influence of OC are enough after 
the age of 30 when resorption is higher than formation during the years of bone maintenance. 
Considering estrogen is an osteoblast protective agent (ESHRE Capri Workshop, 2010), the 
question arises whether the circulating estrogen levels are high enough when bone resorption is 
higher (ages 30+) in comparison to the time of bone acquisition ages (ages 12-18), where 
formation is higher than resorption.  
Typically persons with oligiomenorrhea and anorexia demonstrate positive effects on 
bone mineral accrual from OC use (Liu & Lebrun, 2006). Considering the lowest amount of 
circulating estrogen in a regular menstrual cycle is 30 pol/L (Teirmaa et al., 1998), these erratic 
menstrual cycles may not generate a consistent enough low dose of circulating estrogen lead to 
higher bone resorption. However, even though persons taking OC have a reduced circulating 
estrogen level, they may still have a consistent dose of estrogen. This in itself may maintain 
enough circulating estrogen to regulate bone remodeling.  
Another aspect is to look at further is the physical activity groups within non-user and 
user groups. This may indicate whether PA has had any protective or masking effect on this 
analysis. A study by Burr et al., (2000), indicated that those who exercise and took OC had the 
greatest increase in bone mineral accrual at the FN.  Furthermore, if those who are active have a 
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greater total BMC by approximately 10 % (Baxter-Jones et al., 2011), than those who are less 
active, this may also mask any effects that OC have on bone parameters of active individuals, 
whether it beneficial or detrimental. Even though there were no preliminary differences between 
groups for PA level, considering PA has influence on bone accrual (Bailey et al., 1999), further 
analysis using more sophisticated analytical techniques may give further insight to whether or 
not OC have any benefits or detriment on adolescent, young adult or adult bone health.  The type 
of PA should also be considered as those individuals that are more exposed to the benefits high 
impact loading activities (McKay et al., 2000), may still benefit from continuous accrual of bone 
regardless of detriments hormonal alterations may have. It is important to further research these 
mechanisms on bone accrual and bone maintenance. Singling out each factor that contributes to 
bone mineral acquisition is important in order to get the most benefit from environmental and 
lifestyle choices. 
The finding of decreased TB BMC is consistent with that of Scholes et al., (2010), where 
it was found that adult users of OC, with a mean use of over 3 and half years, had a significant 
decrease in whole body BMD, and the higher decrease in BMD was associated with increase in 
duration of use. It has been suggested that long duration of OC use may be detrimental to TB 
BMC later in life; however, this finding needs to be further assessed into ages 30 through 50, by 
looking at a further duration of use on BMC.  
There was no significant difference at the LS or FN where fracture risk is most 
prominent, an indication that OC use may not enhance osteoporotic bone loss.  OC users did not 
indicate a detriment to LS or FN BMC by the alterations to circulating estrogen and progestin 
levels.  However, analyzing initiation and duration of use may indicate whether timing and 
prolonged use impact healthy BMC levels. 
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5.2 Duration of Use 
 It was hypothesized that longer duration of use would have a negative effect on TB, LS, 
and FN BMC at all sites. However, a positive finding from this study is that duration of use did 
not show any significant detriments at any of the sites tested, at any age. This analysis suggests 
that the TB, LS and FN BMC were not affected by prolonged use of OC. This would suggest that 
the amount of estrogen needed to aid in the balance of cell apoptosis of osteoblasts (Bradford, 
Gerace, Roland, & Chrzan, 2010) is still enough despite the reduced circulating levels regulated 
by OC use. Typically regular menstruation leads to circulation estradiol levels of 143 +/- 78 
pmol/l and 35pg/ml (converts to 128pmol/l) (Teirmaa et al., 1998; Ginther, MaGastal, Gastal, 
Baerwald & Pierson, 2005). Teirmaa et al., (1998) indicated approximately 30-pmol/l level of 
estradiol throughout the 21 days of OC use. This low circulating level may be effective in 
maintaining bone homeostasis and the reason why those with irregular menstruation benefit from 
OC use (Liu & Lebrun, 2006).  
Studies so far have looked at users versus non-users over a short duration of time, Cromer 
et al., (2008) for 2 years and Berenson et al., (2008), for 3 years. This is of interest as our study 
looked at over 20 years of data, and had a mean usage of 7.94 years. This is the first study to 
investigate OC use over 5 years and since the analysis of users versus non-users does not account 
for duration of use the grouping of users into short term and long-term was able to further 
analyze OC use on bone. This study has taken it two steps further in order to analyze the specific 
details of timing of use and years of use.  
Finally, users for over 10 years had no detriment to their BMC, which is interesting 
considering the prolonged levels of reduced peak estrogen levels in the cycle. This is an 
opposing outcome to Scholes et al., (2010) who demonstrated a decrease in BMD with increase 
in duration of use. This discrepancy in findings may be due to the nature of the data analysis in 
the current study, specifically the aligning of participants by skeletal maturation and accounting 
for differences in growth patterns and development.  
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5.3 Initiation of Use 
It was hypothesized that those who initiated OC in the adolescent period would have 
lower BMC at the TB, FN and LS than those who initiated in adulthood and non-users. 
Interesting findings of the study are outcomes that are slightly opposing in respects to initiation 
of use. Participants that had never used OC had significantly greater TB BMC at (BA 20yrs) 32 
years of age, than those who had initiated OC use at BA 7, approximately age 19 or later. There 
was no difference for those that initiated use 1-6 years PPHV at this site at any time point.  This 
would suggest a detriment to late start of OC, which is what was hypothesized; however, it was 
also hypothesized that an early start of OC use would be a detriment, but there was no 
association. Further the data indicates that initiation of OC within adolescence (1-6 PPHV) had a 
significant increase in LS BMC at BA 7, approximately age 19, in comparison to the adult 
initiation (7+ PPHV) LS BMC.  This further refutes the premise that OC use during the delicate 
growing years may deplete optimal bone levels, and may in fact suggest that initiation in 
adolescent years is more beneficial than initiation in young adulthood. At this point the initiation 
of use at an adult age is more controversial than those starting in adolescence, affecting the TB 
BMC as well as the LS BMC. From these findings we can conclude that initiation of OC use 
may be most beneficial during the adolescent years. It should be noted however, that the lack of 
difference between groups at 30 years of age would suggest that this benefit is not prolonged. 
This may have to do with the duration of use for those that initiated in adolescence and leaves the 
question of whether the increase was due to OC use for the entire adolescent period or portion 
thereof.   
Scholes et al., (2010) indicated that users who used for a longer period of time had lower 
BMC, however, timing of maturation was not accounted for within the study and thus bone may 
have shown a detriment that could be confirmed using a longitudinal model.  Using a 
longitudinal design to assess OC use allowed for alignment of maturation using PHV to address 
changes in bone parameters (Tanner, 1962).  Since 20-40% of bone accrual is affected by 
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lifestyle and environmental factors (Ruffing et al., 2007) it was crucial to look at the impact of 
hormonal changes by pharmalogical agents on bone during adolescence, when the majority of 
bone is accrued.  Participants that have already reached adult BMC should still be studied to 
analyze the effects of OC use on BMC; however, it is imperative to account for differences in 
growth and development to compare across individuals, which is why accounting for growth 
prior to and after PHV is essential (Tanner, 1978).  
There were no significant differences at the FN between any of the groups at any age. 
This is of interest since the FN is the first of these sites to obtain peak bone mass, and is one of 
the three most common fragility fracture risk areas. This finding indicates that use of OC on 
bone may not be a detriment and therefore not a risk factor for osteoporosis related fractures. 
Furthermore, with the decrease in age of initiation of use of OC, it is important to include users 
prior to adulthood, as a growing number of users are under the age of 19 and utilizing OC for 
numerous medical conditions. These findings suggest that usage of OC during adolescence can 
be used without a detrimental effect on bone. With the benefit shown in LS BMC, OC did not 
appear to affect the crucial magnitude of bone accrual when initiated in adolescence. Even 
though a majority of users are 20-30 years old, over 25 % of Canadian users (Wilkins et al., 
2000) use OC within 6 years of PPHV. Since a detriment was not found, but a benefit, this 
indicates the possibility to address menstrual irregularities and acne with OC without the penalty 
to BMC and risk of osteoporosis. 
Also, these findings may indicate the impact of OC use on bone in adolescence may not 
be as detrimental to BMC levels as a teenage pregnancy. Pregnant women, provide calcium to 
the fetus for development of the skeleton (NIAMS, 2011).  Ca is provided through the diet, but if 
inadequate will be derived from the stores in the maternal bone; therefore, decreasing BMC 
(NIAMS, 2011).  Teenage pregnancy is a concern, as during the times of optimal bone accrual, 
the calcium is needed for the baby and can lead to low levels of BMC and increase the risk of 
osteoporosis (NIAMS, 2011). The use of OC in adolescence in this study has not shown a 
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detriment, but yet an improvement at the LS BMC; therefore, the continuation of OC 
prescription to prevent teenage pregnancy should still be considered. 
 
5.4 Limitations of the Study 
One of the limitations to this study is that it is an observational study and does not 
regulate uncontrollable factors such as type of OC use and selection of groups. All types of OC 
formulations were included in the study, and most of the users had switched OC brands and 
formulation types; therefore, not allowing for one type of OC to be individually assessed.  A 
RCT would be needed to further solidify the potential benefits of OC use in adolescence found in 
the study. Another limitation of this observational study design is that participants were included 
throughout the study even with only 3 time points. This varied the amount of individuals 
included in the group mean at each age point. At the approximate age of 12, there were over 30 
participants per group, but by age 32 there were only 5 non-users and 6 OC users. This low 
participant number may have contributed to the significant difference in TB BMC at the age of 
32. The mean of 5 non-users and 6 OC users is calculated as a representative of the population 
and the variation in TB BMC between these two groups, due to small numbers, may be 
contributing to this significant difference. Thus this significant finding may be due to a Type 1 
error and therefore caution should be used when considering the real effect of this outcome.  
In this study some retrospective data for OC use was necessary since by the date the 
questionnaire was implemented, some participants were already users. Medical records could be 
used to specifically date time of OC use in combination with questionnaires in order to increase 
reliability between prescription start dates and length of use. Even though most questionnaires 
were given within the timing of initiation of use, some participants did not remember the exact 
times of start of OC use. Additionally, some participants were indicating different start times 
from year to year.  
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Another limitation was the variety of OC types that the users were utilizing. While the 
majority used the OC brand Tri-Cyclen (n=18), other OC types used were Allesse (n=13), 
Marvelon (n=5), Lo-Estren (3), Diane 21 (n=3), Yasmin (n=1), Triquilar (n=1), Min-Ovral 
(n=4), Demulin (n=1), and the Evra Patch (n=1). It was not one brand or formulation of OC but 
rather a multitude of OC formulations. Even though the groups were divided into users and non-
users, OC brands vary in combinations of progesterone and estrogen. These variations may 
separately have an impact on bone health. This study also allowed for a long duration of use to 
be observed. Considering females may change birth control types throughout their duration of 
use, there is no detailed information to which formulation, if any, is causing bone alterations.  
Specifically, a certain brand may be causing a benefit or detriment, and being masked by 
another.  
Another limitation of the study was the low sample size at the later time points of data 
collection. Seven participants per group are needed for 80% statistical power.  As the study 
continues the number of data for time points over 30 years of age will be increased and another 
analysis of the data should be performed to see if any further changes in BMC at the TB, LS and 
FN are evident.  
There are three limitations to the use of DXA to assess bone parameters. One is that DXA 
is a 2 dimensional image of a 3 dimensional object. This does not allow for data to be derived of 
the bone structure and leads to assumptions of bone health based on BMC or aBMD. Second, 
since DXA has only 2 rays to attenuate the 3 different tissues of the body (lean mass, fat mass 
and bone) (Bolotin, Sievanen, & Grashuis, 2003) lean and fat mass data are derived as soft tissue 
and then calculated in order to derive compositions of each. An assumption with DXA is that the 
tissues scanned are consistent (Malina et al., 2004); however, the varying fat mass at the bone 
site between patients may lead to unreliable measures as with increase in fat mass the more soft 
tissue for the ray to attenuate in order to measure the bone (Bolotin et al., 2003).  Further, OC 
use can have an effect on lipid profiles as the 17β-estradiol has shown to increase high-density 
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lipoprotein cholesterol and low-density lipoprotein cholesterol (Bitzer & Simon, 2011). These 
changes in lipid profiles may lead to unreliable measures from patient to patient, and years on 
and off use of OC.  The third limitation of DXA in this study is in 2008 a second machine was 
utilized. Changes in bone mass may be due to the change in equipment and variability between 
machines; however, a conversion equation was applied to the new data to make it comparable 
with the first machine, so this should not be a significant factor.  
 
5.5 Strengths of Study 
The longitudinal aspect of this study as well as the skeletal measurements prior to and 
after maturation are important strengths of this study. With these markers we were able to tease 
out individual growth patterns and align participants by maturational status instead of 
chronological age. This accounts for individual timing and magnitudes of growth and allows for 
a more valuable and reliable comparison. This is the only study to analyze OC use in accordance 
with maturation. Also this is the only study with an OC use data span of over 20 years in relation 
to bone health. 
 
5.6 Future Directions 
  Considering there was a significant decline in TB BMC after the age of 30 in the OC user 
group, it would be imperative to follow this group throughout the next decade of life. 
Also, it is important to look at physical activity groups in comparison with duration of use, to 
assess for any PA benefits to OC users. And finally, a future study needs to look at initiation of 
use and duration of use of those who initiated OC within 1-6 years of PPHV and used OC for 1-5 
years, 5-10 years and 10+ years, in order to determine further answers to why LS BMC was 
greater at 19 years of age in OC users, but did not show a difference later on. Does the combined 
effect of timing of OC initiation and duration of use have an effect on BMC?  Considering that 
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LS BMC went up at 19 years of age for those who initiated 1-6 years PPHV it would be 
interesting to see the interaction between lengths of use within this initiation period.  
 
5.7 Conclusion 
This is the first study to examine the impact of OC use on bone parameters using a 
longitudinal perspective with maturation alignment. Up until now, there have been equivocal 
results in OC use on bone.   The short-term RCT so far in the literature does not account for the 
changes of bone parameters over a long term, or the absence of markers prior to and after 
maturation. Short term RCT or intervention studies neglect the ability to align individuals by 
PHV for maturational reliable comparisons.   
 This study indicated users that initiated OC in adulthood (7 + years PPHV) had less TB 
BMC at 32 years of age than adolescent OC users. It also indicates benefits to LS BMC at 19 
years of age from adolescent initiation of OC use. Interestingly enough there were no detriments 
to the FN site, irrespective of timing of initiation or duration of use at any age point. This is a 
positive finding as the FN is a fracture risk site (Osteoporosis, 2011), which is linked with 
morbidity (Ioannidis et al., 2009). The other benefit of these findings is the LS showed an 
increase at 19 years of age with adolescent initiation of OC use, and otherwise did not show any 
significant differences amongst the analysis. The LS being another significant area of fragility 
fracture risk and increased morbidity, it is important to further assess the question of the 
detriments of OC use on this site.  
In conclusion, the majority of the study hypotheses were not supported, with two 
exceptions: at 32 years of age OC users had significantly more TB BMC than non-users and 
those that initiated OC use in adulthood had significantly more TB BMC at the same age point. 
Given these results it seems promising that OC use in adolescence may not be as detrimental as 
previously hypothesized. 
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APPENDIX B: Consent Form 
Bone Mineral Accrual Study 
College of Kinesiology, University of Saskatchewan 
 
Research Participant Information and Consent Form  
 
 
Principal Investigator    
o Dr. Adam Baxter-Jones, College of Kinesiology, phone 966-1078 
 
Sub-Investigator(s)  
o Dr. Saija Kontulainen, College of Kinesiology 
o Dr. David Leswick, Medical Imaging, RUH   
 
Sponsor 
o Canadian Institute of Health Research, grants no. MOP 83391, ROP 85582 and MOP 
98002. 
 
Introduction: 
You are invited to continue participating in the Bone Mineral Accrual Study. Your participation 
in this study is entirely voluntary and you may withdraw at any time without penalty.  Before 
you decide to participate it is important that you understand what the research involves. This 
consent form will tell you about the study, why the research is being done, and your role as a 
volunteer along with the possible benefits, risks and discomforts involved. If you decide to 
participate you will be required to sign this consent form. Please read this form carefully and feel 
free to ask any questions you might have.   
 
Purpose: 
High peak bone mass and optimal bone structures are important in determining lifetime’s risk of 
osteoporosis. Thus, determination of factors that enhance bone development during growth is 
important in developing intervention strategies for osteoporosis prevention. The Bone Mineral 
Accrual Study is the only study internationally to date to have monitored yearly bone mineral 
accrual through childhood, adolescence and early adulthood. The continuation of testing into the 
adult years will answer the question of when peak bone mass occurs, and identify factors during 
the growing years that affect peak bone mass, structure and strength.  
 
Procedures:  
Procedures will be the same as previous testing. However, this year you have the option of taking 
part in another part of the study, which will involve additional measures of bone structure and 
estimated strength. Assessment of bone, nutrition, physical activity and lifestyle questionnaires, 
anthropometry and the assessment of blood and urine will take place at the College of 
Kinesiology. MRI measures of bone will take place at the Royal University Hospital. The 
following procedures will be performed: 
a) Assessment of Bone Mineral Density and Structure: Your total body, lumbar spine 
and proximal femur bone mineral density will be evaluated using dual-energy x-ray 
absorptiometry (DXA). This procedure is routinely used in clinical medicine. Your 
bone structure will be measured with two peripheral quantitative computer 
tomography (pQCT) scanners. Your wrist, forearm, ankle and calf will be scanned. 
Each scan will take approximately 2 minutes. The effective radiation dose from the 
DXA and pQCT measurements is small, about 23 µSv(micro Sievert). The average 
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annual background radiation in North America due to natural sources is 
approximately 2500 µSv per year. Your hip bone structure will also be measured with 
magnetic resonance imaging (MRI). This will be done in the Royal University 
Hospital. MRI does not produce radiation. 
b) Nutrition, physical activity and lifestyle questionnaires. These are standard 
questionnaires that will ask you to identify your physical activity patterns and typical 
nutritional intake. You will also be asked about other lifestyle behaviors such as 
tobacco and alcohol use. 
c) Anthropometric and muscle strength assessment: Height, weight, waist circumference 
and skinfold thickness will be measured. Your grip strength will be measured by a 
hand held dynamometry and your leg strength by a vertical jump. 
d) Blood assessment and urine: Approximately 5 mL of blood will be drawn from a 
catheter that is inserted into a vein in your arm and you will be asked to provide a 
urine sample. The purpose of the blood and urine collection is to measure indicators 
of health (i.e. glucose, triglycerides and cholesterol). There may be some discomfort 
during the drawing of blood. Although unlikely, there is a risk of bruising and 
infection with the drawing of blood but care will be taken to minimize these risks.  
e) Resting blood pressure will be assessed.  
 
The total time commitment for this study will be approximately three hours.  
 
Potential Benefits: 
The benefits of participating in this experiment include an increased knowledge of your overall 
health status, including bone mass, structure and strength, body composition and activity and 
dietary patterns. There is no guarantee that the participant will receive any direct benefit from the 
study.   
 
Potential Risks: 
The risks of this experiment involve exposure to small amounts of radiation during DXA and 
pQCT scanning.   
 
Research-Related Injury: 
There will be no cost to you for participation in this study. You will not be charged for any 
research procedures. In the event that you become ill or injured as a result of participating in this 
study, necessary medical treatment will be made available at no additional cost to you.  By 
signing this document you do not waive any of your legal rights. 
  
Alternative Procedures or Course of Treatment: 
You do not have to participate in this study to have your body composition assessed. These tests 
can be arranged through appointment in the College of Kinesiology.  
 
New Findings: 
If, during the course of this study, new information becomes available that may relate to your 
willingness to continue to participate, this information will be provided to you by the 
investigators. 
 
Confidentiality:  
While absolute confidentiality cannot be guaranteed, every effort will be made to ensure that the 
information you provide for this study is kept entirely confidential.  Your name will not be 
attached to any information, nor mentioned in any study report, nor be made available to anyone 
except the research team.  It is the intention of the research team to publish results of this 
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research in scientific journals and to present the findings at related conferences and workshops, 
but your identity will not be revealed. 
 
Future consent 
With your permission we may also contact you in the future for reassessment and to provide you 
with your results.   
 
 
 
Right to Withdraw: 
It is understood that you will be free to withdraw from any or all parts of the study at any time 
without penalty.   
 
 
Questions: 
Please be assured that you may ask any question at any time.  We will be glad to discuss your 
results with you when they become available and we welcome your comments and suggestions.  
Should you have any concerns about this study or wish further information please contact: 
 Dr. Adam Baxter-Jones (phone: 966-1078, email baxter.jones@usask.ca) or 
 Dr. Saija Kontulainen (phone: 966-1077, email saija.k@usaks.ca) 
 
 
If you have any questions regarding your rights as a research subject or concerns about your 
experiences while participating in this study, you should contact the Chair of the Biomedical 
Research Board Ethics Board (Bio-REB), c/o, University of Saskatchewan at 306-966-4053.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 62 
APPENDIX C: Lifestyle Questionnaire 
Bone Mineral Accrual Study 
Females Only Questionnaire 
 
 
1. How old were you when you started to have menstrual cycles?_____ years old 
 
Did it occur in: 
 Spring 
 Summer 
 Fall 
 Winter 
 
2. Are you currently using oral contraceptives? 
 No  
 Yes 
 
If yes, for how long have you used them? _____ Years _____ Months 
 
What is the brand name of the oral contraceptives that you use?  __________ 
 
If no, have you used them in the past? 
 
 No  
 Yes 
 
If yes, for how long had you used them?  _____ Years _____ Months 
 
What brand name of oral contraceptives did you use? ___________ 
 
3. How many periods do you have in a year? 
 Over 13 periods 
 9 to 13 periods 
 3 to 8 periods 
 less than 3 periods 
 
4. Have you had a period in the past three months? 
 No 
 Yes 
 
5. What is the date of the first day of your last period? _________________ 
 
6. Have you ever had an absence or loss of periods (pregnancy and lactation not included)? 
 No 
 Yes 
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If yes, at what age(s) did you miss a period(s)? 
   _________ years old 
   _________ years old 
 
For how long did your periods stop? 
   _________mos. ________ yrs 
   _________mos. ________ yrs 
 
 
 
 
Legally, you cannot be scanned if you are pregnant. 
 
7. Are you pregnant? 
 No  
 Yes  
 I don’t know  
 
 
8. How many children have you given birth to? ______ If none, go to next page 
   
List their birthdates: 
 
Child 1: __________________ Did you breastfeed?      
If yes, how many months? ______ 
 
Child 2: __________________ Did you breastfeed?      
If yes, how many months? ______ 
 
Child 3: __________________ Did you breastfeed?      
If yes, how many months? ______ 
 
Child 4: __________________ Did you breastfeed?      
If yes, how many months? ______ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Yes 
 
 No 
 
 Yes 
 
 No 
 
 Yes 
 
 No 
 
 Yes 
 
 No 
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APPENDIX D: 24-Hour Food Recall 
 
University of Saskatchewan 
Bone Mineral Accrual Study 
24 Hour Recall Questionnaire 
 
Name: _________________________  Subject # __________   Date: 
____________________ 
 
Please list every FOOD and DRINK that you ate yesterday 
 
 
Time 
 
Food Items 
 
Type & 
Preparation 
 
Amount 
 
Brand Name or 
Where Bought 
 
Code 
 
Morning 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mid-
morning 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Noon Meal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Midday 
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Evening 
Meal 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Before Bed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EXAMPLE 
 
CEREAL 
 
CORN 
FLAKES 
 
1 cup 
 
Kellogg 
 
 
 
Was this intake usual?  Circle one: Yes No (if No, explain why not 
_____________________________________) 
Did you take any vitamins/minerals during this time? Circle one: Yes No (if Yes, list names: 
_________________ 
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APPENDIX E: Physical Activity Questionnaire 
 
Bone Mineral Accrual Study 
Physical Activity Questionnaire (Adults) 
 
 
We are trying to find out about your level of physical activity from the last 7 days (in the last 
week).  This includes activities that make you sweat, make your legs feel tired, or make you 
breathe hard, such as team sports, running, strenuous occupational activities, and others. 
 
Remember: 
1. There are no right and wrong answers — this is not a test. 
2. Please answer all the questions as honestly and accurately as you can — this is very 
important. 
  
 
1. Physical activity in your spare time: Have you done any of the following activities in the 
past 7 days (last week)?  If yes, how many times? (Mark only one circle per row.) 
 
7 times 
No 1-2 3-4 5-6 or more 
 
Rock climbing.......................       Rowing/canoeing....................         Tennis/squash ........................…       Stair climber (or other  similar equipment)......................       Walking for exercise.................       Heavy yard work ......................       Jogging or running....................       Bicycling ..........................……         Aerobics (or other exercise class)...       Swimming ............................…         Baseball, softball ....................…       Dance ..................................…         Football .................................         Badminton ..........................….         Soccer...................................         Street/floor hockey....................       Volleyball ..............................         Basketball ...........................….         Skating (in‐line/ice)....................       Cross‐country skiing ................…       Ice hockey/ringette ..................…       Martial arts..................…………        Weight training..................…….       Other: _________________________..…         _________________________..…         
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2. In the last 7 days, during the morning, how often were you very active (for example: 
playing sports, exercise classes, strenuous occupational activity, strenuous household 
or child rearing tasks)? (Check one only.) 
 
None...….…..................................................  1 time last week..................................................   2 or 3 times last week.........................................   4 or 5 times last week..........................................  6 or 7 times last week.........................................   
 
3. In the last 7 days, after lunch and before supper, how often were you very active (for 
example: playing sports, exercise classes, strenuous occupational activity, strenuous 
household or child rearing tasks)? (Check one only.) 
 
None...........................................................  1 time last week .................................................   2 or 3 times last week ........................................   4 or 5 times last week.........................................  6 or 7 times last week........................................   
 
4. In the last 7 days, during the evening, how often were you very active (for example: 
playing sports, exercise classes, strenuous occupational activity, strenuous household 
or child rearing tasks)? (Check one only.)   None .........................................................................   1 time last week ...................................................   2 or 3 times last week ........................................   4 or 5 last week.....................................................   6 or 7 times last week ........................................   
 
5. On the last weekend, how often were you very active (for example: playing sports, 
exercise classes, strenuous occupational activity, strenuous household or child rearing 
tasks)? (Check one only.) 
 
None ................................................................…  1 time.................................................................................   2 — 3 times.....................................................................   4 — 5 times.....................................................................   6 or more times.............................................................   
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6. Which one of the following describes you best for the last 7 days?  Read all five 
statements  
 before deciding on the one answer that describes you. 
 
A. All or most of my free time was spent doing things that involve little 
 physical effort ..........................................................................................................
  
 
B. I sometimes (1 — 2 times last week) did physical things in my free time 
 (e.g. played sports, went running, swimming, bike riding, did aerobics) ............ 
  C. I often (3 — 4 times last week) did physical things in my free time ..........…….   D. I quite often (5 — 6 times last week) did physical things in my free time ……..   E. I very often (7 or more times last week) did physical things in my free time. …   
7.   Mark how often you did physical activity (for example: playing sports, exercise 
classes, strenuous occupational activity). 
      Little    Very 
     None   bit Medium Often  often 
         
Monday ...................       
Tuesday ...................       
Wednesday..............       
Thursday.................       
Friday ......................       
Saturday ..................       
Sunday .....................       
 
8. Were you sick last week, or did anything prevent you from doing your normal 
physical activities? (Check one.) 
 
Yes ............................................  
No .......................................................     If Yes, what prevented you? __________________________________ 
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